Skip to content

Psychological Medicine

ISSN 0033-2917, 1469-8978

133 papers in the library · 5,746 citations · publishing 1977-2026

Papers

Sort Most recent Most cited

Robotically-induced auditory-verbal hallucinations: combining self-monitoring and strong perceptual priors.

Psychological Medicine February 1, 2024 Pavo Orepic, Fosco Bernasconi, Melissa Faggella et al. 9 citations

Inducing hallucinations under controlled experimental conditions in non-hallucinating individuals represents a novel research avenue oriented toward understanding complex hallucinatory phenomena, avoiding confounds observed in patients. Auditory-verbal hallucinations (AVH) are one of the most common and distressing psychotic symptoms, whose etiology remains largely unknown. Two prominent...

DOI: 10.1017/s0033291723002222 (opens in new tab) Full text (opens in new tab) Auditory-verbal hallucinations Delusional ideation False alarms Self-monitoring +4

Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.

Psychological Medicine 2024 Brandon Weiss, Induni Ginige, Lu Shannon et al. 38 citations

Psilocybin Therapy (PT) is being increasingly studied as a psychiatric intervention. Personality relates to mental health and can be used to probe the nature of PT's therapeutic action. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, over a core 6-week trial...

Assessing evidence supporting cannabis harm reduction practices for adolescents at clinical high-risk for psychosis: a review and clinical implementation tool.

Psychological Medicine 2024 Simon Kapler, Laura Adery, Gil D Hoftman et al.

Cannabis use is consistently associated with both increased incidence of frank psychotic disorders and acute exacerbations of psychotic symptoms in healthy individuals and people with psychosis spectrum disorders. Although there is uncertainty around causality, cannabis use may be one of a few modifiable risk factors for conversion to psychotic disorders in individuals with Clinical High Risk...

Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model.

Psychological Medicine December 1, 2023 Paul McCrone, Henry Fisher, Clare Knight et al. 34 citations

There is growing evidence to support the use of the psychedelic drug psilocybin for difficult-to-treat depression. This paper compares the cost-effectiveness of psilocybin-assisted psychotherapy (PAP) with conventional medication, cognitive behavioural therapy (CBT), and the combination of conventional medication and CBT. A decision model simulated patient events (response, remission, and...

The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses.

Psychological Medicine November 2023 Matthew N Hill, Margaret Haney, Cecilia J. Hillard et al.

Cannabis is well established to impact affective states, emotion and perceptual processing, primarily through its interactions with the endocannabinoid system. While cannabis use is quite prevalent in many individuals afflicted with psychiatric illnesses, there is considerable controversy as to whether cannabis may worsen these conditions or provide some form of therapeutic benefit. The...

Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol

Psychological Medicine October 17, 2023 Cathy Davies, Matthijs Geert Bossong, Daniel Martins et al. 9 citations

ABSTRACT Background Hippocampal hyperperfusion has been observed in people at Clinical High Risk for Psychosis (CHR), is associated with adverse longitudinal outcomes and represents a potential treatment target for novel pharmacotherapies. Whether cannabidiol (CBD) has ameliorative effects on hippocampal blood flow (rCBF) in CHR patients remains unknown. Methods Using a double-blind,...

Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans.

Psychological Medicine October 1, 2023 Jonathan W. Kanen, Qiang Luo, Mojtaba Rostami Kandroodi et al. 44 citations

The non-selective serotonin 2A (5-HT2A) receptor agonist lysergic acid diethylamide (LSD) holds promise as a treatment for some psychiatric disorders. Psychedelic drugs such as LSD have been suggested to have therapeutic actions through their effects on learning. The behavioural effects of LSD in humans, however, remain incompletely understood. Here we examined how LSD affects probabilistic...

Mindfulness-based cognitive therapy v. treatment as usual in people with bipolar disorder: A multicentre, randomised controlled trial.

Psychological Medicine October 1, 2023 Imke Hanssen, Marloes J. Huijbers, Eline Regeer et al. 7 citations

Mindfulness-based cognitive therapy (MBCT) seems a promising intervention for bipolar disorder (BD), but there is a lack of randomised controlled trials (RCT) investigating this. The purpose of this multicentre, evaluator blinded RCT was to investigate the added value of MBCT to treatment as usual (TAU) in BD up to 15 months follow-up (NCT03507647). A total of 144 participants with BD type I...

DOI: 10.1017/S0033291723000090 (opens in new tab) Full text (opens in new tab) Mindfulness-based cognitive therapy Bipolar disorder Effectiveness Randomised controlled trial

Mindfulness training and exercise differentially impact fear extinction neurocircuitry

Psychological Medicine September 1, 2023 Shaked E. Leibovitz, Gunes Sevinc, Jonathan Greenberg et al. 3 citations

Abstract Background The ability to extinguish a maladaptive conditioned fear response is crucial for healthy emotional processing and resiliency to aversive experiences. Therefore, enhancing fear extinction learning has immense potential emotional and health benefits. Mindfulness training enhances both fear conditioning and recall of extinguished fear; however, its effects on fear extinction...

Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials

Psychological Medicine July 19, 2023 Tehseen Noorani, Gillinder Bedi, Suresh Muthukumaraswamy 49 citations

Abstract What happens when an emerging programme of medical research overlaps with a surging social movement? In this article we draw on the anthropological term ‘chemosociality’ to describe forms of sociality born of shared chemical exposure. Psychedelic administration in the context of recent clinical trials appears to have been particularly chemosocial in nature. We argue that one...

DOI: 10.1017/s0033291723001289 (opens in new tab) Full text (opens in new tab) Sociality Causal inference Context archaeology Clinical trial +4

Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression – CORRIGENDUM

Psychological Medicine July 19, 2023 Brandon Weiss, Induni Ginige, Lu Shannon et al. 1 citation

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.

Varieties of felt presence? Three surveys of presence phenomena and their relations to psychopathology.

Psychological Medicine June 1, 2023 Ben Alderson-Day, Peter Moseley, Kaja Mitrenga et al. 19 citations

Experiences of felt presence (FP) are well documented in neurology, neuropsychology and bereavement research, but systematic research in relation to psychopathology is limited. FP is a feature of sensorimotor disruption in psychosis, hypnagogic experiences, solo pursuits and spiritual encounters, but research comparing these phenomena remains rare. A comparative approach to the phenomenology of...

DOI: 10.1017/s0033291722000344 (opens in new tab) Full text (opens in new tab) Bodily self Dissociation Hallucinations Psychosis +1

Neurophysiological changes associated with vibroacoustically-augmented breath-focused mindfulness for dissociation: targeting interoception and attention

Psychological Medicine May 5, 2023 Negar Fani, Alfonsina Guelfo, Dominique L. la Barrie et al. 10 citations

BACKGROUND: Dissociative symptoms can emerge after trauma and interfere with attentional control and interoception; disruptions to these processes are barriers to mind-body interventions such as breath-focused mindfulness (BFM). To overcome these barriers, we tested the use of an exteroceptive augmentation to BFM, using vibrations equivalent to the amplitude of the auditory waveform of the...

Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case–control study

Psychological Medicine May 4, 2023 Giulia Trotta, Victoria Rodriguez, Diego Quattrone et al.

Abstract Background Childhood adversity and cannabis use are considered independent risk factors for psychosis, but whether different patterns of cannabis use may be acting as mediator between adversity and psychotic disorders has not yet been explored. The aim of this study is to examine whether cannabis use mediates the relationship between childhood adversity and psychosis. Methods Data were...

The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case–control study

Psychological Medicine May 2, 2023 Edoardo Spinazzola, Diego Quattrone, Victoria Rodriguez et al.

Abstract Background While cannabis use is a well-established risk factor for psychosis, little is known about any association between reasons for first using cannabis (RFUC) and later patterns of use and risk of psychosis. Methods We used data from 11 sites of the multicentre European Gene-Environment Interaction (EU-GEI) case–control study. 558 first-episode psychosis patients (FEPp) and 567...

Voice phenomenology as a mirror of the past.

Psychological Medicine May 1, 2023 David Van den Berg, Eva Tolmeijer, Alyssa Jongeneel et al.

Post-traumatic mechanisms are theorised to contribute to voice-hearing in people with psychosis and a history of trauma. Phenomenological links between trauma and voices support this hypothesis, as they suggest post-traumatic processes contribute to the content of, and relationships with, voices. However, research has included small samples and lacked theory-based comprehensive assessments. In...

Reporting of harms in clinical trials of esketamine in depression: a systematic review.

Psychological Medicine April 26, 2023

Abstract: While previous systematic reviews of trials evaluating conventional antidepressants highlighted inadequacies and inconsistencies in adverse event (AE) reporting, no evaluation is available on esketamine in resistant depression. The objective of this review was to assess quality of reporting AEs in all published clinical trials studying esketamine. It also aimed to compare the...

Mindfulness-Oriented Recovery Enhancement remediates anhedonia in chronic opioid use by enhancing neurophysiological responses during savoring of natural rewards.

Psychological Medicine April 1, 2023 Eric L Garland, Spencer T Fix, Justin Hudak et al. 51 citations

Neuropsychopharmacologic effects of long-term opioid therapy (LTOT) in the context of chronic pain may result in subjective anhedonia coupled with decreased attention to natural rewards. Yet, there are no known efficacious treatments for anhedonia and reward deficits associated with chronic opioid use. Mindfulness-Oriented Recovery Enhancement (MORE), a novel behavioral intervention combining...

Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene × environment moderation and mediation.

Psychological Medicine April 1, 2023 Laurent Elkrief, Bochao Lin, Mattia Marchi et al.

It has not yet been determined if the commonly reported cannabis-psychosis association is limited to individuals with pre-existing genetic risk for psychotic disorders. We examined whether the relationship between polygenic risk score for schizophrenia (PRS-Sz) and psychotic-like experiences (PLEs), as measured by the Community Assessment of Psychic Experiences-42 (CAPE-42) questionnaire, is...

DOI: 10.1017/s0033291721003378 (opens in new tab) Full text (opens in new tab) Cannabis Polygenic risk score Psychosis risk Psychotic-like experience

LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model.

Psychological Medicine March 1, 2023 Isabel Wießner, Marcelo Falchi, Fernanda Palhano-Fontes et al. 53 citations

For a century, psychedelics have been investigated as models of psychosis for demonstrating phenomenological similarities with psychotic experiences and as therapeutic models for treating depression, anxiety, and substance use disorders. This study sought to explore this paradoxical relationship connecting key parameters of the psychotic experience, psychotherapy, and psychedelic experience. In...

The independent and combined effects of cannabis use and systemic inflammation during the early stages of psychosis: exploring the two-hit hypothesis.

Psychological Medicine December 1, 2022 Fabiana Corsi-Zuelli, Leonardo Marques, Daiane Leite Da Roza et al.

Cannabis consumption is a modifiable risk factor associated with psychosis, but not all cannabis users develop psychosis. Animal studies suggest that an antecedent active immune system interacts with subsequent cannabis exposure and moderates the cannabis-psychosis association, supporting the two-hit hypothesis. The clinical investigations are few, and it is unclear if the immune system is a...

DOI: 10.1017/s0033291721000726 (opens in new tab) Full text (opens in new tab) Marijuana Adaptive immunity Anti-inflammatory cytokines Inflammation +3

Modulation of the functional connectome in major depressive disorder by ketamine therapy.

Psychological Medicine October 1, 2022 Ashish K Sahib, Joana R Loureiro, Megha M Vasavada et al. 36 citations

Subanesthetic ketamine infusion therapy can produce fast-acting antidepressant effects in patients with major depression. How single and repeated ketamine treatment modulates the whole-brain functional connectome to affect clinical outcomes remains uncharacterized. Data-driven whole brain functional connectivity (FC) analysis was used to identify the functional connections modified by ketamine...

DOI: 10.1017/s0033291720004560 (opens in new tab) Full text (opens in new tab) Ketamine Functional connectivity Major depression Salience network

Bidirectional relationships between cannabis use, anxiety and depressive symptoms in the mediation of the association with psychotic experience: further support for an affective pathway to psychosis

Psychological Medicine September 12, 2022 Rajiv Radhakrishnan, L. Pries, G. Erzin et al.

Abstract Background Empirical evidence suggests that people use cannabis to ameliorate anxiety and depressive symptoms, yet cannabis also acutely worsens psychosis and affective symptoms. However, the temporal relationship between cannabis use, anxiety and depressive symptoms and psychotic experiences (PE) in longitudinal studies is unclear. This may be informed by examination of mutually...

Anterior default mode network and posterior insular connectivity is predictive of depressive symptom reduction following serial ketamine infusion.

Psychological Medicine September 1, 2022 Benjamin Wade, Joana R Loureiro, Ashish K Sahib et al. 18 citations

Ketamine is a rapidly-acting antidepressant treatment with robust response rates. Previous studies have reported that serial ketamine therapy modulates resting state functional connectivity in several large-scale networks, though it remains unknown whether variations in brain structure, function, and connectivity impact subsequent treatment success. We used a data-driven approach to determine...